Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VERVE 102

Next Previous
Drug Profile

VERVE 102

Alternative Names: VERVE-102

Latest Information Update: 05 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Verve Therapeutics
  • Class Antihyperlipidaemics; Gene therapies; RNA
  • Mechanism of Action Gene modulators; PCSK9 protein expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hyperlipoproteinaemia type IIa

Most Recent Events

  • 25 Jul 2025 Verve Therapeutics has been acquired by Eli Lilly and Company
  • 17 Jun 2025 Verve Therapeutics plans to initiate a phase III trial for Hyperlipoproteinaemia type IIa in the US
  • 30 Apr 2025 Pharmacodynamics and adverse event data from the phase Ib Heart-2 trial in Hyperlipoproteinaemia type IIa released by Verve Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top